Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
Note: If you attended the live CE activity AND received CE credit (i.e.
a pharmacist CE statement of credit with ACPE UAN 0221-0000-19-503-L01-P), you are
NOT allowed to also receive credit for this home-study on-demand web activity.
Prior to the development of reversal agents for direct oral anticoagulants (DOACs),
pharmacists and clinicians were left with little choice in managing acute major bleeding.
Assessment of the severity of the bleed is a one of the first steps in determining
if reversal of anticoagulation is necessary. After other initial measures are completed,
should the clinician determine reversal to remain necessary, the decision on which
reversal agent to use becomes critical. Fortunately, specific treatments have been
developed to address this need and new data is continually becoming available to aid
in the selection process.
The goal of this educational activity is to enhance the pharmacist’s knowledge of major bleeding types and assessment. Reversal agent selection and dosing strategies will be reviewed, along with the assessment of the latest safety and efficacy data. A discussion on reversal agent procurement and administration will provide learners with formulary development considerations. This will be an interactive session to include Q&A with the faculty, as well as audience-response polling and decision-making exercises.
The target audience for this activity includes health‐system pharmacists, including chief pharmacy officers and pharmacy directors. At the completion of this activity, the participant will be better able to:
Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP
Professor of Pharmacy Practice and Science
College of Pharmacy
University of Nebraska Medical Center
Katelyn W. Sylvester, PharmD, BCPS, CACP
Pharmacy Manager – Anticoagulation Services
Department of Pharmacy
Brigham and Women’s Hospital
Release Date: 12-10-2019
Expiration Date: 1-15-2021
ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-19-503-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. . Dr. Dobesh has served as a consultant for Boehringer Ingelheim, Janssen Pharmaceuticals, Pfizer/BMS Alliance, and Portola Pharmaceuticals. Dr. Sylvester has served as a consultant for Portola Pharmaceuticals. A portion of grant funds received by ProCE from Portola Pharmaceuticals, Inc. will be used to compensate the faculty for this presentation.
This activity is provided by ProCE, Inc. and is supported by an educational grant from Portola Pharmaceuticals, Inc.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.